A study on the impact of neoadjuvant therapy on molecular subtype conversion in breast cancer
Neoadjuvant therapy can induce molecular subtype heterogeneity in patients with invasive breast cancer. The identification of factors contributing to this heterogeneity may be associated with variations in biological markers of residual disease post-NAC, sampling discrepancies between core needle biopsy (CNB) and surgical specimens, or the selective mutagenic pressure exerted by chemotherapeutic agents.
Authors
- Haijun Yu (ORCID: https://orcid.org/0000-0002-5346-7830)
- Wenqi Cai (ORCID: https://orcid.org/0000-0002-2195-0203)
- Ke Yuan (ORCID: https://orcid.org/0000-0002-2318-1460)
- Runbing Zhang
- Dong Liu (ORCID: https://orcid.org/0000-0002-5233-4796)
- Chaoyan Wu
- Linhui Zheng
Institutions
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1186/s12957-025-03801-6
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province
- Wuhan University
- Zhongnan Hospital of Wuhan University